CHAPTER 1 - MARKET SUMMARY
Market Overview
The Thailand Veterinary Pharmaceuticals Market serves two structurally distinct demand pools: commercial livestock requiring population-level disease prevention and individual companion animals requiring clinic-led care. Department of Livestock Development statistics record approximately 500.8 million chickens, 12.2 million pigs and 9.5 million beef cattle in 2025. This scale creates recurring demand for vaccines, parasiticides, anti-infectives and herd-health therapeutics.
Bangkok Metropolitan Region is the principal commercial, regulatory and technical-services hub, concentrating multinational animal-health offices, regulatory functions and national distributor management. The Thai Animal Health Products Association reports 79 member companies involved in veterinary medicines and related animal-health products. This supplier density supports portfolio competition while making regulatory execution, technical field support and provincial channel reach important differentiators.
Market Value
USD 403 million
2025
Dominant Region
Bangkok Metropolitan Region
2025
Dominant Segment
Animal Type
Product Type fastest growing
Total Number of Players
79
Future Outlook
From a 2025 base of USD 403 million, the Thailand Veterinary Pharmaceuticals Market is projected to reach USD 718 million by 2032, representing an 8.60% CAGR over the seven-year 2025-2032 forecast interval. The pace exceeds the 6.80% historical CAGR recorded during 2020-2025. The model reaches approximately USD 661 million in 2031 before closing at the 2032 terminal value. Growth increasingly comes from preventive biologics, companion-animal specialty therapy, parasite control and technically supported disease-management portfolios rather than animal-population growth alone.
Value growth is expected to remain above treatment-equivalent volume growth as product mix becomes more specialized. Companion-animal pharmaceuticals are modelled to increase from 29.0% of revenue in 2025 to 38.0% by 2032, while vaccines and immunologicals increase from 25.0% to 31.0%. The broader Thailand veterinary-medicine market was independently benchmarked at USD 428.8 million in 2025, which provides a close external sizing bracket after adjusting for the narrower pharmaceutical scope used in this report.
8.60%
Forecast CAGR
USD 718 Mn
2030 Projection
Base Year
2025
Historical Period
2020-2025
Forecast Period
2025-2032
Historical CAGR
6.80%
CHAPTER 2 - SCOPE OF REPORT
Scope of the Market
CHAPTER 3 - Key Stakeholders
Key Target Audience
Key stakeholders who can leverage from this market analysis for investment, strategy, and operational planning.
Investors
CAGR, biologics mix, regulatory risk, margins, consolidation, returns
Corporates
portfolio registration, cold-chain reliability, channel reach, farm access
Government
AMR stewardship, vaccine coverage, biosecurity, import dependence, resilience
Operators
dose compliance, inventory availability, cold-chain integrity, technical support
Financial institutions
receivables cycle, import exposure, inventory finance, demand resilience
CHAPTER 4 - Market Size & Growth
Market Size, Growth Forecast and Trends
This section evaluates the historical market size, analyzes year-over-year growth dynamics, and presents forecast projections supported by market performance indicators and demand-side drivers.
Historical & Projected Market Size ($ Million)
Year-over-Year Growth Rate (%)
Market Value vs Volume Growth (%)
Historical Market Performance (2020-2025)
The historical period shows a clear post-2021 normalization. Annual growth reached its trough at 3.79% in 2021 before accelerating above 7% in every year from 2022 through 2025. The treatment-equivalent volume index advanced from 100.0 in 2020 to 124.3 in 2025, demonstrating that expansion reflected genuine treatment-intensity gains as well as portfolio mix. Production animals remained the principal demand base, while companion-animal medicines contributed a progressively higher-value clinic-led revenue stream.
Forecast Market Outlook (2025-2032)
The forecast closes at USD 718 million in 2032 with an 8.60% CAGR, while treatment-equivalent volume reaches an index value of 184.9. Annual value growth remains approximately 2.6-3.0 percentage points above treatment-volume growth in most forecast years. This gap reflects biologics, premium pet therapeutics, technical-service intensity and higher-value preventive products. Growth is therefore expected to be more mix-driven than the historical cycle, increasing the importance of registered portfolio breadth, disease-specific innovation and channel execution.
CHAPTER 5 - Market Data
Market Breakdown
Thailand's veterinary-pharmaceutical growth trajectory combines expanding treatment activity with a gradual shift toward premium companion-animal medicines and preventive biologics. For CEOs and investors, portfolio quality, regulatory execution and service-supported distribution increasingly determine value capture.
Year | Market Size (USD Mn) | YoY Growth (%) | Companion Animal Revenue Mix (%) | Vaccines & Immunologicals Revenue Mix (%) | Treatment-Equivalent Volume Index (2020=100) | Period |
|---|---|---|---|---|---|---|
| 2020 | $290 Mn | +- | 21.0% | 21.0% | Forecast | |
| 2021 | $301 Mn | +3.79% | 22.0% | 21.8% | Forecast | |
| 2022 | $324 Mn | +7.64% | 23.5% | 22.6% | Forecast | |
| 2023 | $349 Mn | +7.72% | 25.0% | 23.5% | Forecast | |
| 2024 | $376 Mn | +7.74% | 27.0% | 24.2% | Forecast | |
| 2025 | $403 Mn | +7.18% | 29.0% | 25.0% | Forecast | |
| 2026 | $438 Mn | +8.68% | 30.2% | 25.8% | Forecast | |
| 2027 | $475 Mn | +8.45% | 31.5% | 26.6% | Forecast | |
| 2028 | $516 Mn | +8.63% | 32.8% | 27.4% | Forecast | |
| 2029 | $561 Mn | +8.72% | 34.1% | 28.3% | Forecast | |
| 2030 | $609 Mn | +8.56% | 35.4% | 29.2% | Forecast | |
| 2031 | $661 Mn | +8.54% | 36.7% | 30.1% | Forecast | |
| 2032 | $718 Mn | +8.62% | 38.0% | 31.0% | Forecast |
Companion Animal Revenue Mix
29.0% (2025, Thailand). Premium clinic-led products offer attractive portfolio economics. An independent pet-medicine benchmark reached USD 116.8 million (2025, Thailand), with biologics identified as the fastest-growing product segment.
Vaccines & Immunologicals Revenue Mix
25.0% (2025, Thailand). Preventive biologics create recurring treatment protocols and technical differentiation. Customs recorded USD 160.2 million (2024, Thailand) of HS 300239 veterinary-vaccine-class imports, demonstrating substantial biologics supply-chain exposure.
Treatment-Equivalent Volume Index
124.3 (2025, Thailand). Rising treatment intensity provides the operational base for value growth. Feed-industry projections show approximately 21.84 million tonnes (2025F, Thailand) of animal-feed demand, indicating the scale of commercial production requiring systematic health management.
CHAPTER 6 - Segmentation
Market Segmentation Framework
Comprehensive analysis across key dimensions providing insights into market structure, consumer preferences, and distribution patterns.
No of Segments
7
Dominant Segment
Animal Type
Fastest Growing Segment
Product Type
Product Type
Animal Type
Distribution Channel
Formulation
Therapeutic Area
End User
Geography
Key Segmentation Takeaways
Comprehensive analysis across all extracted segmentation dimensions providing insights into market structure, consumer preferences, and distribution patterns.
Animal Type
Animal type provides the clearest demand-allocation lens because Thailand combines large-scale commercial poultry and swine production with increasingly premium companion-animal care. Food-Producing Poultry remains the largest absolute treatment pool, while Companion Animals contribute higher-value clinic economics and faster portfolio sophistication. Aquaculture creates a separate technical channel requiring species-specific disease-management and farm-support capabilities.
Product Type
Product mix is the fastest-evolving dimension as disease prevention, antimicrobial stewardship and premium pet care shift spending toward Vaccines & Immunologicals, Parasiticides and Specialty Therapeutics. Biologics benefit from recurring disease-control protocols and high technical-service requirements, while anti-infective portfolios increasingly depend on stewardship-compatible indications and evidence-based veterinary use rather than routine volume expansion.
CHAPTER 7 - Regional Analysis
Regional Analysis
Thailand ranks among the largest veterinary-pharmaceutical markets in Southeast Asia after country estimates are normalized to comparable pharmaceutical and biologic scope. Indonesia remains larger in absolute value, while Thailand combines industrial livestock density with a comparatively developed companion-animal medicine pool and above-peer forecast growth. kenresearch.com
Focus Country Ranking
2nd
Focus Country Market Size
USD 403 Mn (2025)
Thailand CAGR (2025-2032)
8.60%
Focus Country Ranking
2nd
Focus Country Market Size
USD 403 Mn (2025)
Thailand CAGR (2025-2032)
8.60%
Regional Analysis (Current Year)
Regional Analysis Comparison
| Metric | Indonesia | Thailand | Vietnam | Philippines | Malaysia |
|---|---|---|---|---|---|
| Market Size (USD Mn, 2025) | 455 | 403 | 185 | 170 | 115 |
| CAGR (%) (2025-2032) | 7.20% | 8.60% | 7.90% | 6.70% | 6.30% |
| Broad Veterinary Medicine Anchor (USD Mn, 2025) | 479 | 429 | 200 | 181 | 121 |
| Veterinary Product Regulatory Structure (2025) | National veterinary-product registration with domestic and import supply channels | Separate chemical and biologic registration pathways with biologics controls | Veterinary-drug registration covering imported and domestic supply | Registered importer, distributor and animal-health regulatory framework | National veterinary-product controls supported by licensed distribution |
Market Position
Thailand ranks 2nd in the selected five-country peer set at USD 403 million in 2025, supported by diversified livestock and companion-animal demand rather than a single species pool. kenresearch.com
Growth Advantage
Thailand's 8.60% CAGR exceeds Vietnam's 7.90% and Indonesia's 7.20%, positioning the country as the fastest-growing normalized veterinary-pharmaceutical market within the selected peer group. kenresearch.com
Competitive Strengths
Thailand combines 500.8 million chickens with an observable association ecosystem of 79 animal-health companies, supporting scale, portfolio diversity, technical services and nationwide distribution capability.
CHAPTER 8 - INDUSTRY ANALYSIS
Growth Drivers, Challenges & Opportunities
Comprehensive analysis of key factors shaping the Thailand Veterinary Pharmaceuticals Market, including growth catalysts, operational challenges, and emerging opportunities across production, distribution, and consumer segments.
Growth Drivers
Commercial Livestock Intensity Sustains Recurring Treatment Demand
- Broiler production accounts for 8.47 million tonnes of feed demand and 38.79% of the national feed mix (2025F, Thailand). High throughput makes vaccination schedules, respiratory-disease control and preventive flock-health programs economically important to integrated poultry producers and pharmaceutical suppliers.
- Swine represents 5.30 million tonnes and 24.28% of feed demand (2025F, Thailand). Large commercial herds create recurring opportunities across anti-infectives, vaccines, parasiticides and reproductive-health products, particularly for suppliers able to bundle diagnostics-informed technical support with registered pharmaceutical portfolios.
- Layer-hen demand accounts for 2.28 million tonnes and 10.43% of national feed requirements (2025F, Thailand). Long production cycles increase the economic value of preventive medicine, flock immunity and biosecurity because health disruptions affect egg output over extended periods.
Companion-Animal Healthcare Premiumization
- Owned dogs reached approximately 3.45 million animals (2025, Thailand). The scale creates a recurring base for parasiticides, dermatology products, pain management and vaccination, with premium clinic channels capturing value from routine preventive and chronic-care protocols.
- Owned cats reached approximately 1.94 million animals (2025, Thailand). Cats are a commercially important growth cohort for preventive medicines and specialty therapy, broadening revenue beyond dog-focused portfolios and supporting investment in species-specific formulations and veterinary education.
- The owned-pet population expanded approximately 6% year on year (2025, Thailand). Continued population growth increases the lifetime treatment base, benefiting suppliers with clinic access, preventive-care portfolios and products suited to long-term companion-animal healthcare rather than episodic acute treatment.
Preventive Biologics and Disease-Control Requirements
- Official FMD protocols specify a second cattle dose 3-4 weeks after initial vaccination (2025, Thailand). Repeat administration converts disease prevention into recurring pharmaceutical demand and increases the importance of reliable vaccine availability, cold-chain handling and veterinarian-supported compliance.
- Routine FMD revaccination is recommended every 6 months for beef cattle (2025, Thailand), while dairy cattle require more frequent protection. Repeat protocols support predictable biologics demand and reward suppliers capable of managing inventory and technical field execution across provincial livestock clusters.
- A 2025 autogenous-vaccine seminar involved 120 public- and private-sector participants (2025, Thailand), highlighting institutional interest in farm-specific biologics. Standardized autogenous approaches could create specialist revenue pools for local manufacturing, diagnostics-linked vaccines and outbreak-response services.
Market Challenges
Long Regulatory Approval Cycles
- Certain non-new veterinary medicines require approximately 120 business days (current Thai FDA standard, Thailand). Launch delays can reduce first-mover advantage and increase inventory-planning risk, favoring firms with experienced local regulatory teams and disciplined submission management.
- Veterinary portfolios are separated into chemical and biological regulatory pathways (current framework, Thailand). Firms spanning both categories must maintain distinct evidence packages, quality controls and specialist capabilities, increasing fixed regulatory costs for smaller entrants.
- Biologics require dedicated regulatory and quality oversight, including product-specific controls that raise operating complexity. The 220-day new-product timeline (current Thai FDA standard, Thailand) makes launch sequencing and local regulatory capability strategic components of market-entry economics.
Antimicrobial Stewardship Compresses Routine Antibiotic Volume
- Human antibiotic use declined 26% against a 20% target (six-year review, Thailand), reflecting broad national stewardship rather than an animal-only intervention. Veterinary companies therefore face sustained pressure to demonstrate responsible use and shift innovation toward prevention and precision treatment.
- Thailand's AMR-management capability increased from 3.0 to 4.2 out of 5 (six-year review, Thailand). Stronger surveillance and stewardship reduce the attractiveness of undifferentiated antibiotic-volume strategies while increasing demand for vaccines, biosecurity and evidence-based therapeutic portfolios.
- The national surveillance platform now publishes consumption trends through 2024 data (current Thai SAC series, Thailand). Greater visibility increases accountability for suppliers and end users, favoring products with clear therapeutic indications and documented stewardship compatibility.
Import Dependence and Cold-Chain Exposure
- The United States supplied approximately USD 53.1 million (2024, Thailand imports) of HS 300239 veterinary-vaccine-class products. Concentration in a limited number of international manufacturing bases makes supply resilience and safety stock commercially important.
- The Netherlands contributed approximately USD 28.9 million (2024, Thailand imports). European biologics exposure increases the importance of validated cold-chain logistics, import documentation and coordinated forecasting between manufacturers and Thai distribution partners.
- Spain supplied approximately USD 20.7 million (2024, Thailand imports). The multi-origin sourcing model diversifies product availability but increases regulatory-document management and inventory complexity for distributors handling multiple biological-product registrations.
Market Opportunities
Premium Companion Biologics and Specialty Therapeutics
- The independently benchmarked pet-medicine pool reached USD 116.8 million (2025, Thailand). Suppliers can monetize this through premium vaccines, parasiticides, dermatology products and specialty chronic-care therapies sold through veterinarians rather than competing solely on production-animal volume.
- Thailand had approximately 3.45 million owned dogs (2025, Thailand). Companies with clinic education, adherence programs and broad preventive portfolios can capture recurring value across annual vaccination, parasite control and age-related treatment needs.
- Owned cats reached approximately 1.94 million animals (2025, Thailand). Realizing this opportunity requires continued species-specific product registration, veterinary education and formulations suited to feline administration and compliance.
Preventive Vaccine Portfolio Localization
- Official FMD products cover 3 virus types (2025, Thailand), illustrating the technical complexity of local disease protection. Manufacturers and technology partners can capture value by aligning product development with Thailand-specific epidemiology and government disease-control requirements.
- Routine beef-cattle FMD revaccination occurs every 6 months (2025 protocol, Thailand). Recurring schedules create predictable demand for reliable local availability, offering distributors and manufacturers an opportunity to improve inventory resilience and service continuity.
- Thailand launched the VaxHub system and an autogenous IBH vaccine on 19 August 2025 (Thailand). Commercial opportunity depends on scaling validated local biologics manufacturing, clear regulatory pathways and integration with farm-level disease surveillance.
Provincial Technical-Service and Distribution Expansion
- Lopburi has approximately 54.2 million chickens and 10.83% of Thailand's chicken inventory (2025, Thailand). A dedicated technical-service hub can improve vaccination execution, disease response, distributor productivity and direct relationships with integrators.
- Chonburi holds approximately 41.6 million chickens and 8.31% of national inventory (2025, Thailand). Suppliers can benefit through regional stock positioning, poultry-specialist veterinarians and rapid-response technical coverage that reduces product-availability risk for large farms.
- Kanchanaburi has approximately 37.9 million chickens and 7.57% of national inventory (2025, Thailand). Capturing this demand requires local distributor capability, cold-chain discipline and field teams able to integrate disease management with commercial farm protocols.
CHAPTER 9 - Competitive Landscape
Competitive Landscape Overview
Competition combines large multinational portfolios with established domestic manufacturers and distributors. Registration depth, biologics capability, technical services, farm and clinic coverage, product availability and local manufacturing determine competitive strength.
Market Share Distribution
Top 5 Players
Market Dynamics
8 new entrants in the past 5 years, indicating strong market attractiveness and growth potential.
Company Name | Market Share | Headquarters | Founding Year | Core Market Focus |
|---|---|---|---|---|
Zoetis (Thailand) Limited | - | Bangkok, Thailand | - | Companion-animal and livestock medicines, vaccines and preventive health |
Boehringer Ingelheim Animal Health (Thailand) Ltd. | - | Bangkok, Thailand | - | Livestock and companion-animal vaccines and therapeutics |
Intervet (Thailand) Co., Ltd. (MSD Animal Health) | - | Bangkok, Thailand | - | Veterinary vaccines, pharmaceuticals and species-focused preventive care |
Elanco (Thailand) Ltd. | - | Bangkok, Thailand | - | Livestock productivity, parasiticides and companion-animal therapeutics |
Ceva Animal Health (Thailand) Ltd. | - | Bangkok, Thailand | - | Poultry, swine and companion-animal vaccines and medicines |
Virbac (Thailand) Co., Ltd. | - | Nonthaburi, Thailand | - | Companion-animal therapeutics, parasiticides and veterinary specialty products |
Animal Health (Thailand) Co., Ltd. (HIPRA) | - | Bangkok, Thailand | - | Preventive biologics and livestock vaccination portfolios |
Better Pharma Co., Ltd. | - | Bangkok, Thailand | - | Locally manufactured veterinary pharmaceuticals and animal-health products |
Bioscience Animal Health Public Company Limited | - | Nonthaburi, Thailand | 2004 | Veterinary medicines, vaccines, livestock, aquaculture and companion-animal solutions |
Advance Pharma Co., Ltd. | - | Bangkok, Thailand | - | Veterinary medicines for terrestrial livestock and aquaculture |
Cross Comparison Parameters
The report provides detailed cross-comparison of key players across 10 performance parameters to identify competitive strengths and weaknesses.
Registered Veterinary Product Portfolio
Provincial Distribution Coverage
Thailand Animal-Health Revenue Growth
Gross Margin
Analysis Covered
Market Share Analysis:
Benchmarks local competitive scale using disclosed revenue and portfolio evidence.
Cross Comparison Matrix:
Compares portfolio, channel, operating, and financial capabilities across verified players.
SWOT Analysis:
Assesses regulatory, portfolio, localization, channel, and innovation advantages by company.
Pricing Strategy Analysis:
Evaluates vaccine, therapeutic, tender, clinic, and distributor pricing approaches comparatively.
Company Profiles:
Maps verified Thailand presence, headquarters, portfolio focus, and competitive role.
CHAPTER 10 - REPORT TOC
Market Report Structure
Comprehensive coverage across three strategic phases - Market Assessment, Go-To-Market Strategy, and Survey - delivering end-to-end insights from market analysis and execution roadmap to customer demand validation.
Market Assessment Phase
Supply-side and competitive intelligence covering market sizing, segmentation, competitive dynamics, regulatory landscape, and future forecasts.
Go-To-Market Strategy Phase
15 chapters
Entry strategy evaluation, execution roadmap, partner recommendations, and profitability outlook.
Survey Phase
8 chapters
Demand-side primary research conducted through structured interviews and online surveys with end users across priority metros and Tier 2/3 cities to capture consumption behavior, unmet needs, and purchase drivers.
Complete Report Coverage
201+ detailed sections covering every aspect of the market
143
Assessment Sections
58
Strategy Sections
CHAPTER 11 - Our Approach
Research Methodology
Desk Research
- Reviewed veterinary drug registration pathways
- Mapped livestock species demand indicators
- Analyzed veterinary vaccine import flows
- Benchmarked national animal-health supplier participation
Primary Research
- Animal-health commercial directors interviewed nationally
- Veterinary regulatory affairs managers consulted
- Livestock technical-service veterinarians interviewed provincially
- Veterinary hospital procurement heads consulted
Validation and Triangulation
- 250 stakeholder responses triangulated across channels
- Supplier revenues reconciled against portfolios
- Species demand proxies checked independently
- Forecast closure tested across scenarios
CHAPTER 12 - FAQ
FAQs
Still have questions?
Our research team is here to help you find the right solution
CHAPTER 13 - Related Research
Explore Related Reports
Expand your market intelligence with complementary research across regions and adjacent markets.
Regional/Country ReportsRelated market analysis across key regions
Related market analysis across key regions
- Malaysia Veterinary Pharmaceuticals Market Size, Share & Forecast, By Product Type, Animal Type & Distribution Channel, 2025-2032
- Australia Veterinary Pharmaceuticals Market Size, Share & Forecast, By Product Type, Animal Type & Distribution Channel, 2025–2032
- New Zealand Veterinary Pharmaceuticals Market Report Size Share Growth Drivers Trends Opportunities & Forecast 2025–2030
- Japan Veterinary Pharmaceuticals Market Report Size Share Growth Drivers Trends Opportunities & Forecast 2025–2030
- Bahrain Veterinary Pharmaceuticals Market Report Size Share Growth Drivers Trends Opportunities & Forecast 2025–2030
Adjacent ReportsRelated markets and complementary research
Related markets and complementary research
- Mexico Veterinary Diagnostic Equipment Market
- UAE Animal Feed Additives Market Size Share Growth Drivers Trends Opportunities & Forecast 2025–2030
- Thailand Pet Nutrition Products Market
- South Korea Companion Animal Care Market
- Germany Vaccination Supply Chain Market
500+
Market Research Reports
50+
Countries Covered
15+
Industry Verticals